|
2011 |
Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: in vitro, in vivo, and NMR-based structural studies. |
Tally Largent-Milnes, PhD, Frank Porreca, PhD, Todd Vanderah, PhD |
|
2011 |
Targeting mitochondrial bioenergetics for Alzheimer's prevention and treatment. |
Roberta Diaz Brinton, Ph.D |
|
2011 |
Neuroregenerative mechanisms of allopregnanolone in Alzheimer's disease. |
Roberta Diaz Brinton, Ph.D |
|
2011 |
2-Deoxy-D-glucose treatment induces ketogenesis, sustains mitochondrial function, and reduces pathology in female mouse model of Alzheimer's disease. |
Roberta Diaz Brinton, Ph.D |
|
2011 |
Inhibition of p38-MAPK signaling pathway attenuates breast cancer induced bone pain and disease progression in a murine model of cancer-induced bone pain. |
Frank Porreca, PhD, Todd Vanderah, PhD |
|
2010 |
Oxidative stress increases blood-brain barrier permeability and induces alterations in occludin during hypoxia-reoxygenation. |
Thomas P Davis, PhD, Jeffrey J. Lochhead, PhD |
|
2010 |
Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA. |
Tally Largent-Milnes, PhD, Todd Vanderah, PhD |
|
2010 |
Decline in mitochondrial bioenergetics and shift to ketogenic profile in brain during reproductive senescence. |
Roberta Diaz Brinton, Ph.D |
|
2010 |
Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance. |
Tally Largent-Milnes, PhD, Frank Porreca, PhD, Todd Vanderah, PhD |
|
2010 |
Recently patented and promising ORL-1 ligands: where have we been and where are we going? |
Tally Largent-Milnes, PhD, Todd Vanderah, PhD |
|
2010 |
Preserved heart function and maintained response to cardiac stresses in a genetic model of cardiomyocyte-targeted deficiency of cyclooxygenase-2. |
John M. Streicher, PhD |
|
2010 |
MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart. |
John M. Streicher, PhD |
|
2010 |
A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss. |
Tally Largent-Milnes, PhD, Patrick W Mantyh, Todd Vanderah, PhD |
|
2010 |
Menopause and mitochondria: windows into estrogen effects on Alzheimer's disease risk and therapy. |
Roberta Diaz Brinton, Ph.D |
|
2009 |
Frontiers proposal. National Institute on Aging "bench to bedside: estrogen as a case study". |
Roberta Diaz Brinton, Ph.D |
|
2009 |
Progesterone increases rat neural progenitor cell cycle gene expression and proliferation via extracellularly regulated kinase and progesterone receptor membrane components 1 and 2. |
Roberta Diaz Brinton, Ph.D |
|
2009 |
Occludin oligomeric assemblies at tight junctions of the blood-brain barrier are altered by hypoxia and reoxygenation stress. |
Jeffrey J. Lochhead, PhD |
|
2009 |
Expression of bile acid transporting proteins in Barrett's esophagus and esophageal adenocarcinoma. |
|
|
2009 |
Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. |
Roberta Diaz Brinton, Ph.D |
|
2009 |
Estrogen-induced plasticity from cells to circuits: predictions for cognitive function. |
Roberta Diaz Brinton, Ph.D |
|
2009 |
Novel bifunctional peptides as opioid agonists and NK-1 antagonists. |
Tally Largent-Milnes, PhD, Edita Navratilova, Frank Porreca, PhD, Todd Vanderah, PhD |
|
2008 |
DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. |
|
|
2008 |
Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer's disease. |
Roberta Diaz Brinton, Ph.D |
|
2008 |
The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications. |
Roberta Diaz Brinton, Ph.D |
|
2008 |
Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells. |
|
